Suicide in the course of the treatment of depression

Journal of Psychopharmacology

Volumn 13, Issue 1, 1999, Pages 94-99

  Healy, D ^a   Langmaak, C ^a   Savage, M ^a  

^a BANGOR UNIVERSITY   (United Kingdom)

Author keywords

Akathisia; Antidepressants; Behavioural toxicity; Case reports; Suicide

Indexed keywords

ANTIDEPRESSANT AGENT; CLOMIPRAMINE; FLUOXETINE; LOFEPRAMINE; MIANSERIN; MOCLOBEMIDE;

AKATHISIA; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DEPRESSION; DRUG OVERDOSE; HUMAN; METHODOLOGY; NERVOUSNESS; PHARMACOGENETICS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SUICIDE; TREATMENT FAILURE;

EID: 0033061974     PISSN: 02698811     EISSN: None     Source Type: Journal    
DOI: 10.1177/026988119901300110     Document Type: Article

References (61)

1. Ayd F Jr (1996) Lexicon for psychiatry, neurology and neuroscience, p. 268. Williams & Wilkins, Baltimore
2. Beasley C (1991) Fluoxetine and suicide. BMJ 303: 1200
3. Beasley C M, Dornseif B E, Bosomworth J C, Sayler M E, Rampey A H, Heiligenstein J H, Thompson V L, Murphy D J, Masica D N (1991) Fluoxetine and suicide: a meta-analysis of controlled trials of treatment for depression. BMJ 303: 685-692
4. Blacker R, Clare A (1987) Depressive disorder in primary care. Br J Psychiatry 150: 737-751
5. Cassidy S L, Henry J A (1987) Fatal toxicity of antidepressant drugs in overdose. BMJ 295: 1021-1024
6. Creaney W, Murray I, Healy D (1991) Antidepressant induced suicidal ideation. Hum Psychopharmacol 6: 329-332
7. Damluji N F, Ferguson J M (1988) Paradoxical worsening of depressive symptoms caused by antidepressants. J Clin Psychopharmacol 8: 347-349
8. Davies D L, Shepherd M (1955) Reserpine in the treatment of anxious and depressed patients. Lancet 117-120
9. Edwards G (1992) Antidepressants and murder. Psychiatr Bull 16: 537-539
10. Fawcett J, Scheftner W A, Fogg L, Clark D C, Young M A, Hedeker D, Gibbons R (1990) Time-related predictors of suicide in major affective disorders. Am J Psychiatry 147: 1189-1194
11. Fawcett J (1992) Suicide risk factors in depressive disorders and in panic disorder. J Clin Psychiatry 53: 9-13
12. Girard M (1987) Conclusiveness of rechallenge in the interpretation of adverse drug reactions. Br J Clin Pharmacology 23: 73-79
13. Guze S, Robins E (1970) Suicide and primary affective disorder: a study of 95 cases. Br J Psychiatry 117: 437-438
14. Hagnell O, Lanke J, Rorsman B (1981) Suicide rates in the Lundby study: mental illness as a risk factor for suicide. Neuropsychobiology 7: 248-253
15. Healy D (1994) The fluoxetine and suicide controversy. CNS Drugs 1: 223-231
16. Healy D (1997) The antidepressant era. Harvard University Press, Cambridge, MA
17. Healy D (1998) Meta-analysis of trials comparing antidepressants with active placebos. Br J Psychiatry 172: 232-234
18. Healy D, Farquhar G N (1998) Responses to droperidol in healthy volunteers. Hum Psychopharmacol 13: 113-120
19. Healy D, Savage M (1998) Reserpine exhumed. Br J Psychiatry 172: 376-378
20. Henry J A (1992) The safety of antidepressants. Br J Psychiatry 160: 439-441
21. Hill A B (1966) Reflections on the controlled trial. Ann Rheum Dis 25: 107-113
22. Inskip H M, Harris E C, Barraclough B (1998) Lifetime risk of suicide for affective disorder, alcoholism and schizophrenia. Br J Psychiatry 172: 35-37
23. Isacsson G, Holmgren P, Wasserman D, Bergman U (1994) Use of antidepressants among people committing suicide in Sweden. BMJ 308: 506-509
24. Jick H, Ulcickas M, Dean A (1992) Comparison of frequencies of suicidal tendencies among patients receiving fluoxetine, lofepramine, mianserin or trazodone. Pharmacotherapy 12: 451-454
25. Jick S, Dean A D, Jick H (1995) Antidepressants and suicide. BMJ 310: 215-218
26. Joyce P R, Mulder R T, Cloninger C R (1994) Temperament predicts clomipramine and desipramine responses in major depression. J Affective Disorders 30: 35-46
27. Karch F E, Lasagna L (1977) Towards the operational identification of adverse drug reactions. Clin Pharmacol Therapeut 21: 247-253
28. Kazdin A (1982) Single-case research designs. Oxford University Press, New York
29. Kessler R C, McGonagle K A, Zhao S, Nelson C B, Hughes M, Eshleman S, Wittchen H U, Kendler K S (1994) Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States: results from the National Co-morbidity study. Arch Gen Psychiatry 51: 8-19
30. Kielholz P, Battegay R (1958) The treatment of depressive states: with special reference to Tofranil, a new antidepressive. Schweizerische Medizinische Wochenschrift 88: 763-767
31. Kielholz P (1971) Diagnose und Therapie der Depressionen fur Praktiker. JF Lehmanns, Munich
32. King R A, Riddle M A, Chappell P B, Hardin M T, Anderson G M, Lombroso P, Scahill L (1991) Emergence of self-destructive phenomena in children and adolescents during fluoxetine treatment. J Am Acad Child Adolesc Psychiatry 30: 171-176
33. Knorring von L, Bingefors K (1998) Resistant depression: the need for better antidepressants. In Briley M, Montgomery S (eds), Antidepressant therapy at the dawn of the third millennium, pp. 319-332. Martin Dunitz, London
34. Leber P (1998) Managing uncertainty. In Healy D (ed.), The psychopharmacologists, Vol. 2. Chapman & Hall, London
35. Lingjaerde O, Ahlfors U G, Bech P, Dencker S J, Eigen K (1987) The UKU side-effect rating scale. Acta Psychiatr Scand 76(Suppl.): 334
36. Lipinski J F, Mallya G, Zimmerman P et al. (1989) Fluoxetine induced akathisia: clinical and theoretical implications. J Clin Psychiatry 50: 339-342
37. Lopez-Ibor J J, Guelfi J, Pletan Y, Tournox A, Prost J F (1996) Milnacipram and selective serotonin reuptake inhibitors in major depression. Int Clin Psychopharmacol 11 (Suppl. 4): 41-46
38. Moller H-J (1992) Attempted suicide: efficacy of different aftercare strategies. Int Clin Psychopharmacol 6 (Suppl. 6): 58-69
39. Montgomery S A, Montgomery D B (1982) Pharmacological prevention of suicidal behaviour. J Affect Disord 4: 291-298
40. Montgomery S A, Dunner D L, Dunbar G C (1995) Reduction of suicidal thoughts with paroxetine in comparison with reference antidepressants and placebo. Eur Neuropsychopharmacol 5: 5-13
41. Nakielny J (1994) The fluoxetine and suicide controversy. A review of the evidence. CNS Drugs 2: 252-253
42. Pare C M B, Rees W L, Sainsbury M J (1962) Differentiation of two genetically specific types of depression by the responses to antidepressants. Lancet 1340-1343
43. Patterson W M (1993) Fluoxetine-induced sexual dysfunction. J Clin Psychiatry 54: 71
44. Pinder R (1988) The risks and benefits of antidepressant drugs. Human Psychopharmacology 3: 73-86
45. Plewes J M, Koke S C, Sayler M E (1997) Adverse events and treatment discontinuations in fluoxetine clinical trials: an updated meta-analysis. Eur Neuropsychopharmacol 7: S169
46. Rothschild A J, Locke C A (1991) Re-exposure to fluoxetine after serious suicide attempts by 3 patients: the role of akathisia. J Clin Psychiatry 52: 491-493
47. Rouillon F, Phillips R, Serrurier D, Ansart E, Gerard M J (1989) Rechutes de dépression unipolaire et efficacité de la maprotiline. L'Encéphale 15: 527-534
48. Rutz W, von Knorring L, Pihlgren H, Rihmer Z, Walinder J (1995) An educational project on depression and its consequences: is frequency of major depression among Swedish men underrated resulting in high suicidality? Primary Care Psychiatry 1: 59-63
49. Sachdev P (1995) Akathisia and restless legs. Cambridge University Press, Cambridge
50. Staehelin J (1955) Über Depressionszustände. Schweiz Med Wochenschrift 85: 1205
51. Stark P, Hardison C D (1985) A review of multicenter controlled studies of fluoxetine versus imipramine and placebo in outpatients with major depressive disorder. J Clin Psychiatry 46: 53-58
52. Stecklow S, Johannes L (1997) Questions arise on new drug testing. Drug makers relied on clinical researchers who now await trial. Wall Street Journal 15 August
53. Stephens M (1983) Deliberate drug rechallenge. Hum Toxicol 2: 573-577
54. Teicher M H, Glod C, Cole J O (1990) Emergence of intense suicidal preoccupation during fluoxetine treatment. Am J Psychiatry 147: 207-210
55. Teicher M H, Glod C, Cole J O (1991) Dr Teicher and associates reply. Am J Psychiatry 147: 1692-1693
56. Teicher M H, Glod C, Cole J O (1990c) Dr Teicher and associates reply. Am J Psychiatry 148: 1260-1262
57. Tollefson G D, Greist J H, Jefferson J W, Heiligenstein J H, Sayler M E, Tollefson S L, Koback K (1994) Is baseline agitation a relative contra-indication for a SSRI: a comparative trial of fluoxetine versus imipramine. J Clin Psychopharmacol 14: 385-391
58. Van der Sande R, Van Rooijen L, Buskens E, Allart E, Hawton K, Van der Graaf Y, Van Engeland H (1997) Intensive in-patient and community intervention versus routine care after attempted suicide. Br J Psychiatry 171: 35-41
59. Wheatley D, van Moffaert M, Timmerman L et al. (1998) Mirtazapine: efficiency and tolerability in comparison with fluoxetine in patients with major depression. J Clin Psychiatry (in press)
60. WHO (1994) International monitoring of adverse reactions to drugs. Adverse reaction terminology. WHO, Geneva
61. Wirshing W C, Van Putten T, Rosenberg J, Marder S, Ames D, Hicks-Gray T (1992) Fluoxetine, akathisia and suicidality: is there a causal connection? Arch Gen Psychiatry 49: 580-581